The policy stagnation of recent years, where change has been almost entirely focused on pricing, belies a history of significant structural shifts to ensure the program can better accommodate patient needs. …
The system can innovate for patients, when it wants, but history shows it rarely involves HTA
May 31, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Vinnies named inaugural partner of Pharmacy Guild Foundation
August 18, 2026 - - Latest News -
Opportunity #2 - AI can democratise HTA and the negotiations must not squander it
August 18, 2026 - - Latest News -
Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 - - Latest News -
Mesoblast completes treatment in pivotal low back pain trial as phase 3 readout approaches
August 17, 2026 - - Australian Biotech -
Dimerix takes control of US development pathway for new kidney injury treatment
August 17, 2026 - - Australian Biotech -
OncoSil secures FDA approval for targeted bile duct cancer device
August 17, 2026 - - Latest News -
Has any patient ever said they accept a rejection because of the Kaplan-Meier curve?
August 17, 2026 - - Latest News